Lartruvo Purple Book BLA 761038

BLA number
761038
Proprietary names
Lartruvo
Proper names
olaratumab
Applicant
Eli Lilly and Company
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Lartruvoolaratumab351(a)500MG/50ML (10MG/ML)InjectionIntravenousSingle-Dose VialDiscVoluntarily Revoked2016-10-19
002Lartruvoolaratumab351(a)190MG/19ML (10MG/ML)InjectionIntravenousSingle-Dose VialDiscVoluntarily Revoked2017-07-10

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-08-01U001Lartruvo351(a)DiscEli Lilly and Company
2021-08-01U002Lartruvo351(a)DiscEli Lilly and Company
2020-08-01U001Lartruvo351(a)DiscEli Lilly and Company
2020-08-01U002Lartruvo351(a)DiscEli Lilly and Company
2020-05-01R001Lartruvo351(a)RxEli Lilly and Company
2020-05-01R002Lartruvo351(a)RxEli Lilly and Company

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Lartruvo351(a)DiscVoluntarily Revoked2016-10-19
2020-08-01002Lartruvo351(a)DiscVoluntarily Revoked2017-07-10
2020-05-01001Lartruvo351(a)RxVoluntarily Revoked2016-10-19
2020-05-01002Lartruvo351(a)RxVoluntarily Revoked2017-07-10